Get the Stockscreener App
10.46
2.25%
-0.2258
Aardvark Therapeutics Inc stock is traded at $10.46, with a volume of 21,591.
It is down -2.25% in the last 24 hours and down -35.01% over the past month.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
See More
Previous Close:
$10.69
Open:
$10.66
24h Volume:
21,591
Relative Volume:
0.14
Market Cap:
$225.65M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-10.61%
1M Performance:
-35.01%
6M Performance:
-18.74%
1Y Performance:
+0.00%
1-Day Range:
$10.30
$10.74
1-Week Range:
$10.23
$12.16
52-Week Range:
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Name
Aardvark Therapeutics Inc
Sector
Industry
Phone
(858) 225-7696
Address
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
10.40 | 231.90M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.44 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
636.71 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.80 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.56 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.88 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-29-25 | Initiated | Stifel | Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Initiated | BofA Securities | Buy |
| Mar-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-10-25 | Initiated | Morgan Stanley | Overweight |
| Mar-10-25 | Initiated | RBC Capital Mkts | Outperform |
View All
Aardvark Therapeutics Inc Stock (AARD) Latest News
Aardvark Therapeutics (NASDAQ: AARD) sets Nov 11 & Nov 24 investor talks; live webcasts - Stock Titan
Real time social sentiment graph for Aardvark Therapeutics Inc.2025 Sector Review & Low Risk High Reward Ideas - newser.com
Will Aardvark Therapeutics Inc. stock attract ESG investorsTake Profit & Low Drawdown Investment Ideas - newser.com
Will Aardvark Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Action & Target Return Focused Picks - newser.com
Is Aardvark Therapeutics Inc. stock undervalued vs historical averagesPortfolio Performance Summary & Step-by-Step Swing Trade Plans - newser.com
Is Aardvark Therapeutics Inc. forming a reversal patternRate Hike & Weekly High Conviction Ideas - newser.com
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Will Aardvark Therapeutics Inc. stock beat EPS estimates2025 Sector Review & Real-Time Buy Signal Notifications - newser.com
Using AI based signals to follow Aardvark Therapeutics Inc.Trade Analysis Summary & Real-Time Price Movement Reports - newser.com
Analyzing Aardvark Therapeutics Inc. with multi timeframe chartsJuly 2025 EndofMonth & Fast Entry High Yield Stock Tips - newser.com
Is Aardvark Therapeutics Inc. forming a bottoming baseVolume Spike & Weekly Breakout Watchlists - newser.com
Is Aardvark Therapeutics Inc. stock attractive for income investors2025 Market WrapUp & Safe Entry Point Identification - newser.com
Is Aardvark Therapeutics Inc. building a consolidation baseGap Down & Free Long-Term Investment Growth Plans - newser.com
Aardvark Therapeutics Advances PWS Treatment with ARD-101 Study - TipRanks
Aardvark Therapeutics’ ARD-101 Study: A New Hope for Prader-Willi Syndrome - TipRanks
Aardvark Therapeutics Inc Stock (AARD) Financials Data
There is no financial data for Aardvark Therapeutics Inc (AARD). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Aardvark Therapeutics Inc Stock (AARD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jones Bryan | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,250 |
5,300 |
1,250 |
| Lee Tien-Li | Chief Executive Officer |
Sep 15 '25 |
Buy |
9.66 |
10,000 |
96,624 |
1,543,384 |
0.21%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):